NCT04948333 2026-03-18
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Phase 3 Completed
Clinical Trials
9 trialsNCT04487236 2025-08-11
Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors
Suzhou Zanrong Pharma Limited
Phase 1 Completed
NCT02278250 2023-03-16
First in Human Study of M4344 in Participants With Advanced Solid Tumors
EMD Serono
Phase 1 Completed
NCT01976741 2021-05-06
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
Bayer
Phase 1 Completed
NCT03516071 2019-09-04
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
Zai Lab (Hong Kong), Ltd.
Phase 2 Completed
NCT00509821 2019-04-05
Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma
Eli Lilly and Company
Phase 2 Completed
NCT01243346 2018-06-28
Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene
Arog Pharmaceuticals, Inc.
Phase 2 Completed
NCT01433731 2016-03-24
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
TetraLogic Pharmaceuticals
Phase 1 Completed
NCT00751205 2014-10-28
Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)
Bayer
Phase 2 Completed